Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Hepatitis A vaccine not widely used for Hepatitis C patients

25.08.2005


A new study examining whether patients with chronic Hepatitis C virus (HCV) were routinely vaccinated against Hepatitis A virus (HAV) found that vaccination rates were low, even though HAV vaccination is recommended for patients with chronic liver disease.



The results of this study appear in the September 2005 issue of Hepatology, the official journal of the American Association for the Study of Liver Diseases (AASLD). Published by John Wiley & Sons, Inc., Hepatology is available online via Wiley InterScience at http://www.interscience.wiley.com/journal/hepatology.

The HAV vaccine has been available since 1995, yet HAV infection continues to be one of the most preventable illnesses in the United States. It can cause severe liver disease, liver failure, and even death in patients who already have chronic liver disease. HAV vaccination was recommended for these patients by the 1996 Advisory Committee on Immunization Practices and numerous other health agencies, but it is not known to what extent it is being carried out.


Researchers led by Edmund J. Bini, M.D., M.P.H of the New York University School of Medicine identified 1,193 patients from January to December 2000 at the Veterans Affairs New York Harbor Healthcare System in New York who had chronic HCV infection. Follow-up information was collected through June 30, 2002 to determine the number of patients who were tested for HAV and the number who actually received the HAV vaccine. Patients were considered to be vaccinated if they received at least one dose of the vaccine. The study also examined the number of vaccine doses received, the proportion of patients who were susceptible to HAV among those tested (indicated by a negative HAV antibody result), the incidence of HAV infection during follow-up and the number of visits patients made to their primary care provider.

The results showed that 53.6 percent of the 1,193 patients had antibody testing performed, and almost half of these were susceptible to HAV infection. Yet only 94 patients received the HAV vaccine and of these, 45 received only 1 dose. Among the 94 patients who received the vaccine, 88 had been tested for HAV antibody. A total of 3 patients with HCV infection developed acute HAV infection, one of whom died of liver failure. All of them were known to be susceptible to HAV, but none had received the vaccine.

"The low rates of HAV testing and vaccination are striking given the presence of recommendations to vaccinate these individuals against HAV since 1996, the long duration of follow-up, and the high number of visits with their primary care provider," the authors state. "These findings have substantial public health implications and represent missed opportunities for prevention."

The authors speculate that the reasons for the low vaccination rates could include patient refusal (such as a belief that patients weren’t at risk for HAV infection, doubts about the vaccine’s effectiveness, or misconceptions about side effects), a lack of knowledge on the part of health care providers, a lack of resources, or because of a greater need to address more pressing health issues during medical visits.

The authors conclude: "Public health efforts at raising awareness about HAV vaccination in patients with chronic liver disease should be strongly encouraged. In addition, further studies to evaluate patient and provider barriers to HAV vaccination are needed to prevent future missed opportunities for vaccination."

David Greenberg | EurekAlert!
Further information:
http://www.interscience.wiley.com/journal/hepatology

More articles from Studies and Analyses:

nachricht Win-win strategies for climate and food security
02.10.2017 | International Institute for Applied Systems Analysis (IIASA)

nachricht The personality factor: How to foster the sharing of research data
06.09.2017 | ZBW – Leibniz-Informationszentrum Wirtschaft

All articles from Studies and Analyses >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Salmonella as a tumour medication

HZI researchers developed a bacterial strain that can be used in cancer therapy

Salmonellae are dangerous pathogens that enter the body via contaminated food and can cause severe infections. But these bacteria are also known to target...

Im Focus: Neutron star merger directly observed for the first time

University of Maryland researchers contribute to historic detection of gravitational waves and light created by event

On August 17, 2017, at 12:41:04 UTC, scientists made the first direct observation of a merger between two neutron stars--the dense, collapsed cores that remain...

Im Focus: Breaking: the first light from two neutron stars merging

Seven new papers describe the first-ever detection of light from a gravitational wave source. The event, caused by two neutron stars colliding and merging together, was dubbed GW170817 because it sent ripples through space-time that reached Earth on 2017 August 17. Around the world, hundreds of excited astronomers mobilized quickly and were able to observe the event using numerous telescopes, providing a wealth of new data.

Previous detections of gravitational waves have all involved the merger of two black holes, a feat that won the 2017 Nobel Prize in Physics earlier this month....

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

3rd Symposium on Driving Simulation

23.10.2017 | Event News

ASEAN Member States discuss the future role of renewable energy

17.10.2017 | Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

 
Latest News

Microfluidics probe 'cholesterol' of the oil industry

23.10.2017 | Life Sciences

Gamma rays will reach beyond the limits of light

23.10.2017 | Physics and Astronomy

The end of pneumonia? New vaccine offers hope

23.10.2017 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>